Mergers & Acquisitions ·
Pulmatrix stockholders approve reverse split of up to 1-for-10 and merger with Eos SENOLYTIX
PULMPulmatrix, Inc.
Pulmatrix, Inc. stockholders approved key proposals at a special meeting held on October 26, 2026, including the proposed merger with Eos SENOLYTIX, Inc., an amendment to effect a reverse stock split of up to 1-for-10, and an increase in authorized common shares from 200 million to 250 million. The merger involves issuing shares representing more than 20% of Pulmatrix's pre-merger outstanding stock to Eos stakeholders. Additionally, shareholders ratified the independent auditor appointment and elected directors Michael J. Higgins and Anand Varadan. Pulmatrix operates in the biopharmaceutical industry.